Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
|Articles|December 1, 2017
- Pharmaceutical Executive-12-01-2017
- Volume 37
- Issue 12
Pharmaceutical Executive, December 2017 Issue (PDF)
Click the title above to open the Pharmaceutical Executive December 2017 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 9 years ago
Global Health: Fighting the Good Fightalmost 9 years ago
Global Health: Partnerships Hold the Keyalmost 9 years ago
First Foray into Digital Adherencealmost 9 years ago
Global Health: Messages of Hopealmost 9 years ago
A Year of Transformation for Science & Medicinealmost 9 years ago
Access and Reimbursement for Adoptive T-Cell Transfer Drugsalmost 9 years ago
Will Europe Turn a Corner in Personalized Medicine?almost 9 years ago
Fulfilling the Vision of Science: AstraZeneca's Ruud Dobberalmost 9 years ago
Country Report: CanadaAdvertisement
Related to this article
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Viatris is acquiring Pacira BioSciences for $1.65 billion in cash, adding non-opioid pain therapies Exparel and Zilretta.
Ultragenyx is selling it's Rare Pediatric Disease Priority Review Voucher earned for Genglycos’s approval for $210 million.
Pharma logistics are overqualified by design — and how agentic AI can now optimize across thousands of lanes in days, not months.
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.
ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
3
Before You Sign with a New Hub Vendor, Ask These Four Questions
4
ESC 2026: GLP-1–Based Therapies Move Further into Mainstream Cardiovascular Care
5